Pharmaceuticals India News
  • Home
  • Brands
    • Alkem
    • Apollo Hospital
    • Aurobindo Pharma
    • Biocon
    • Cipla
    • Divi’s Laboratories
    • Dr Reddy’s
    • Fortis
    • Glenmark
    • Lupin
    • Mankind Pharma
    • Natco
    • Pfizer
    • Piramal Pharma
    • Sun Pharma
    • Torrent Pharma
    • Zydus
Select Page

Mankind Pharma slapped with INR 83 lakh GST penalty, to file appeal.

by Team Small News | Nov 16, 2025 | Mankind, Pharma

Mankind Pharma, a leading Indian pharmaceutical company, has been slapped with a Goods and Services Tax (GST) penalty of INR 83 lakh (approximately USD 110,000) by the GST authorities. The penalty was imposed due to alleged irregularities in the company’s GST...
The US Food and Drug Administration (USFDA) has conducted an inspection of Unit 1 at Divi’s Laboratories Limited.

The US Food and Drug Administration (USFDA) has conducted an inspection of Unit 1 at Divi’s Laboratories Limited.

by Team Small News | Nov 16, 2025 | Divi's Laboratories

The US Food and Drug Administration (USFDA) recently conducted an inspection of Unit 1 of Divi’s Laboratories Limited, a leading pharmaceutical company based in India. The inspection was a routine evaluation of the company’s compliance with current Good...

Natco Pharma’s Q2 net profit plunges 23.44% to Rs 517.9 crore

by Team Small News | Nov 15, 2025 | Natco, Pharma

Natco Pharma, a leading Indian pharmaceutical company, has reported a decline in its net profit for the second quarter (Q2) of the current financial year. The company’s net profit stood at Rs 517.9 crore, which represents a decline of 23.44% compared to the same...

Lupin earns impressive S&P Global ESG score of 91, establishing a new standard for sustainability in the pharmaceutical industry

by Team Small News | Nov 15, 2025 | Lupin, Pharma

Lupin Limited, a global pharmaceutical company, has achieved a significant milestone by securing an S&P Global ESG Score of 91 for 2025. This score places the company among a select group of pharmaceutical organizations that have crossed the 90-point threshold,...

Invest in Aurobindo Pharma with a projected target price of Rs 1350, as recommended by Motilal Oswal.

by Team Small News | Nov 12, 2025 | Aurobindo Pharma, Pharma

Motilal Oswal has recommended a “buy” rating for Aurobindo Pharma, with a target price of Rs 1350. The brokerage firm is optimistic about the company’s future prospects, driven by its strong product pipeline, increasing presence in the US market, and...
« Older Entries
Next Entries »

_________

Pharna Brands

  • Alkem
  • Apollo Hospital
  • Aurobindo Pharma
  • Biocon
  • Cipla
  • Divi’s Laboratories
  • Dr Reddy’s
  • Fortis
  • Glenmark
  • Lupin
  • Mankind Pharma
  • Natco
  • Pfizer
  • Piramal Pharma
  • Sun Pharma
  • Torrent Pharma
  • Zydus
  • Alkem
  • Apollo Hospital
  • Aurobindo Pharma
  • Biocon
  • Cipla
  • Torrent Pharma
  • Divi’s Laboratories
  • Dr Reddy’s
  • Fortis
  • Glenmark
  • Lupin
  • Zydus
  • Mankind Pharma
  • Natco
  • Pfizer
  • Piramal Pharma
  • Sun Pharma

    Designed by Elegant Themes | Powered by WordPress